Poly (ADP-ribose) polymerase (PARP) as target for the treatment of epithelial ovarian cancer: what to know

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics. 2018 CA Cancer J Clin. 2018;681:7–30.
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Cancer Facts & Figures 2018. Available at www.cancer.org/research/cancer-facts-statistics/all-cancer-factsfigures/cancer-facts-figures-2018.html.
   Google Scholar
• Kroeger PT, Drapkin R. Pathogenesis and heterogeneity of ovarian cancer. Curr Opin Obstet Gynecol. 2017 Feb;29(1):26–34.
   PubMed Web of Science ®Google Scholar
• Kurman RJ, Shih I. The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded. Am J Pathol. 2016;186(4):733–747.
   PubMed Web of Science ®Google Scholar
• Gilks CB, Prat J. Ovarian carcinoma pathology and genetics: recent advances. Hum Pathol. 2009;40(9):1213–1223.
   PubMed Web of Science ®Google Scholar
• Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics. CA Cancer J Clin. 2018 Jul;68(4):284–296. 2018.
   PubMed Web of Science ®Google Scholar
• Armstrong DK, Alvarez RD, Bakkum-Gamez JN, et al. Ovarian Cancer, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. Version 1.2019. J Natl Compr Canc Netw. 2019 Aug 1;17(8):896–909.
   PubMedGoogle Scholar
• Jiang X, Yang J, Yu M, et al. Oncofertility in patients with stage I epithelial ovarian cancer: fertility-sparing surgery in young women of reproductive age. World J Surg Oncol. 2017 Aug 15;15(1):154.
   PubMedGoogle Scholar
• Schorge JO, Eisenhauer EE, Chi DS. Current surgical management of ovarian cancer. Hematol Oncol Clin North Am. 2012 Feb;26(1):93–109.
   PubMed Web of Science ®Google Scholar
• Lawrie TA, Winter-Roach BA, Heus P, et al. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst Rev. 2015 Dec 17;(12). CD004706. DOI:10.1002/14651858.CD004706.pub5.
   Web of Science ®Google Scholar
• Morrison J, Haldar K, Kehoe S, et al. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst Rev. 2012 Aug 15; (8). CD005343. DOI:10.1002/14651858.CD005343.pub3.
   Web of Science ®Google Scholar
• Wright AA, Bohlke K, Armstrong DK, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. Gynecol Oncol. 2016 Oct;143(1):3–15.
   PubMed Web of Science ®Google Scholar
• Ledermann JA, Raja FA, Fotopoulou C, et al. Sessaet C al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. vi24–vi32 Ann Oncol. 2013;24\(suppl 6):vi24-vi32.
   PubMedGoogle Scholar
• Oza AM, Cook AD, Pfisterer J, et al. Pujade-Lauraine. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015 Aug;16(8):928–936.
   PubMed Web of Science ®Google Scholar
• Scott CL, Swisher EM, Kaufmann SH. Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. J Clin Oncol. 2015 Apr 20;33(12):1397–1406.
   PubMed Web of Science ®Google Scholar
• McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 2006 Aug 15;66(16):8109–8115.
   PubMed Web of Science ®Google Scholar
• Gibson BA, Kraus WL. New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs. Nat Rev Mol Cell Biol. 2012 Jun 20;13(7):411–424.
   PubMed Web of Science ®Google Scholar
• Olaparib tablets [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals, Inc.; 2018. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208558s006lbl.pdf.
   Google Scholar
• Rucaparib tablets [prescribing information]. Boulder, CO: Clovis Oncology, Inc.; 2018. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209115s003lbl.pdf.
   Google Scholar
• Niraparib capsules [prescribing information]. Waltham, MA: TESARO Inc.; 2017. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208447lbl.pdf.
   Google Scholar
• Boussios S, Karihtala P, Moschetta M, et al. Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach. Invest New Drugs. 2020;38(1):181–193.
   PubMed Web of Science ®Google Scholar
• Boussios S, Abson C, Moschetta M, et al. Poly (ADP-Ribose) Polymerase Inhibitors: talazoparib in Ovarian Cancer and Beyond. Drugs R D. 2020;20(2):55–73.
   PubMed Web of Science ®Google Scholar
• Rivkin SE, Iriarte D, Sloan H, et al. A phase IB/II trial with expansion of patients at the MTD trial of olaparib plus weekly (metronomic) carboplatin and paclitaxel in relapsed ovarian cancer patients. J Clin Oncol. 2015;33(15_suppl):5573.
   Web of Science ®Google Scholar
• Liu JF, Barry WT, Birrer M, et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol. 2014 Oct;15(11):1207–1214.
   PubMed Web of Science ®Google Scholar
• Hewitt G, Korolchuk VI, Repair R. Recycle: the Expanding Role of Autophagy in Genome Maintenance. Trends Cell Biol. 2017 May;Vol. 27(No):5.
   Google Scholar
• Lodish H, Berk A, Matsudaira P, et al. Molecular Biology of the Cell. 5th ed ed. New York: WH Freeman; 2004. p. p. 963.
   Google Scholar
• Watson JD, Baker TA, Bell SP, et al. Molecular Biology of the Gene, Ch. 9, 10. OCL, 5th ed ed. Pearson Benjamin Cummings; CSHL Press, 2004:C 936762772.
   Google Scholar
• Szostak JW, Orr-Weaver TL, Rothstein RJ, et al. The double-strand-break repair model for recombination. Cell. 1983 May;33(1):25–35.
   PubMed Web of Science ®Google Scholar
• Zhao W, Wiese C, Kwon Y, et al. BRCA Tumor Suppressor Network in Chromosome Damage Repair by Homologous Recombination. Annu Rev Biochem. 2019 Jun 20;88(1):221–245 .
   PubMedGoogle Scholar
• Venkitaraman AR. Cancer suppression by the chromosome custodians, BRCA1 and BRCA2. Science. 2014 Mar 28;343(6178):1470–1475.
   PubMed Web of Science ®Google Scholar
• Boussios S, Mikropoulos C, Samartzis E, et al. Wise Management of Ovarian Cancer: on the Cutting Edge. J Pers Med. 2020 May 21;10(2):41 .
   PubMed Web of Science ®Google Scholar
• Staropoli N, Ciliberto D, Del Giudice T, et al. The Era of PARP inhibitors in ovarian cancer: “Class Action” or not? A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2018Nov;131:83–89.
   PubMed Web of Science ®Google Scholar
• Pommier Y, O’Connor MJ, De Bono J. Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action. Sci Transl Med. 2016 Oct 26;8(362):362ps17.
   PubMed Web of Science ®Google Scholar
• Amé JC, Spenlehauer C, De Murcia G. The PARP superfamily. Bioessays. 2004 Aug;26(8):882–893 .
   PubMed Web of Science ®Google Scholar
• D’Amours D, Desnoyers S, D’Silva I, et al. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem J. 1999 Sep ;1(2):249–268. 342 (Pt 2) \(Pt 2).
   Google Scholar
• Amé JC, Rolli V, Schreiber V, et al. PARP-2, A Novel Mammalian DNA Damage-dependent Poly(ADP-ribose) Polymerase. J Biol Chem. 1999;274(25):17860–17868.
   PubMed Web of Science ®Google Scholar
• Satoh MS, Lindahl T. Role of poly(ADP-ribose) formation in DNA repair. Nature. 1992;356(6367):356–358.
   PubMed Web of Science ®Google Scholar
• D’Arcangelo M, Drew Y, Plummer R; Chapter 4 - The role of PARP in DNA repair and its therapeutic exploitation. DNA Repair in Cancer Therapy (Second Edition) Molecular Targets and Clinical Applications 2016, Pages 115–134. 10.1016/B978-0-12-803582-5.00004-8
   Google Scholar
• Ohmoto A, Yachida S. Current status of poly(ADP-ribose) polymerase inhibitors and future directions. Oncol Targets Ther. 2017 Oct 26;10: 5195–5208.
   PubMed Web of Science ®Google Scholar
• Konstantinopoulos PA, Matulonis UA. PARP inhibitors in ovarian cancer: a trailblazing and transformative journey. Clin Can- cer Res. 2018;24(17):4062–4065.
   PubMed Web of Science ®Google Scholar
• Franzese E, Centonze S, Diana A, et al. PARP inhibitors in ovarian cancer. Cancer Treat Rev. 2019Feb;73:1–9.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011 Jun 29;474(7353):609–615.
   PubMed Web of Science ®Google Scholar
• Kurnit KC, Coleman RL, Westin SN. Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer. Curr Treat Options Oncol. 2018 Nov 15;19(12):1 .
   PubMed Web of Science ®Google Scholar
• Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366(15):1382–1392.
   PubMed Web of Science ®Google Scholar
• Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015 Jan 20;33(3):244–250 .
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum- sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT- Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(9):1274e1284.
   Web of Science ®Google Scholar
• Poveda A, Floquet A, Ledermann JA, et al. Final overall survival (OS) results from SOLO2/ENGOT-ov21: a phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation. J Clin Onco. 2020;38(15):6002. _suppl.
   Web of Science ®Google Scholar
• Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379(26):2495–2505.
   PubMed Web of Science ®Google Scholar
• Penson RT, Valencia RV, Cibula D, et al. 3rd, Bidziński M, et al. Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): a Randomized Phase III Trial. J Clin Oncol. 2020 Apr 10;38(11):1164–1174.
   PubMed Web of Science ®Google Scholar
• Jones P, Wilcoxen K, Rowley M, et al. (ADP-ribose) Polymerase (PARP) Inhibitor for the treatment of tumors with defective homologous recombination. J Med Chem. 2015 Apr 23;58(8):3302–3314.
   PubMed Web of Science ®Google Scholar
• Sandhu SK, Schelman WR, Wilding G, et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2013 Aug;14(9):882–892.
   PubMed Web of Science ®Google Scholar
• Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016 Dec 1;375(22):2154–2164.
   PubMed Web of Science ®Google Scholar
• Moore KN, Secord AA, Geller MA, et al. Niraparib Monotherapy for Late-Line Treatment of Ovarian Cancer (QUADRA): a Multicentre, Open-Label, Single-Arm, Phase 2 Trial. Lancet Oncol. 2019 May;20(5):636–648.
   PubMed Web of Science ®Google Scholar
• González-Martín A, A Pothuri B, Vergote I, et al. Niraparib in Patients With Newly Diagnosed Advanced Ovarian Cancer. Engl J Med. 2019 Dec 19;381(25):2391–2402.
   PubMed Web of Science ®Google Scholar
• Kim DS, Camacho CV, Nagari A, et al. Activation of PARP-1 by snoRNAs controls ribosome biogenesis and cell growth via the RNA helicase DDX21. Mol Cell. 2019 Sep 19;75(6):1270–1285.
   PubMed Web of Science ®Google Scholar
• Kristeleit R, Shapiro GI, Burris HA, et al. A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors. Clin Cancer Res. 2017;23(15):4095–4106.
   PubMed Web of Science ®Google Scholar
• Swisher EM, Lin KK, Oza AM, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017;18(1):75–87.
   PubMed Web of Science ®Google Scholar
• Oza AM, Tinker AV, Oaknin A, et al. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high- grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: integrated analysis of data from Study 10 and ARIEL2. Gynecol Oncol. 2017;147(2):267–275.
   PubMed Web of Science ®Google Scholar
• Ledermann JA, Oza AM, Lorusso D, et al. Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 May;21(5):710–722.
   PubMed Web of Science ®Google Scholar
• Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10106):1949–1961.
   PubMed Web of Science ®Google Scholar
• Shen Y, Rehman FL, Feng Y, et al. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin Cancer Res. 2013;19(18):5003–5015.
   PubMed Web of Science ®Google Scholar
• Murai J, Huang SY, Renaud A, et al. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther. 2014 Feb;13(2):433–443.
   PubMed Web of Science ®Google Scholar
• Pommier Y, O’connorm J, De Bono J. Laying a Trap to Kill Cancer Cells: PARP Inhibitors and Their Mechanisms of Action. Sci Transl Med. 2016 Oct 26;8(362):362ps17.
   PubMed Web of Science ®Google Scholar
• De Bono J, Ramanathan RK, Mina L, et al. Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers. Cancer Discov. 2017;7(6):620–629.
   PubMed Web of Science ®Google Scholar
• Donawho CK, Luo Y, Luo Y, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res. 2007 May;13(9):2728–2737.
   PubMed Web of Science ®Google Scholar
• Puhalla S, Beumer JH, Pahuja S, et al. RG, et al. Final results of a phase 1 study of single-agent veliparib (V) in patients (pts) with either BRCA1/2-mutated cancer (BRCA+), platinum-refractory ovarian, or basal-like breast cancer (BRCA-wt). (Suppl): abstract 2570. J Clin Oncol. 2014;3215_suppl:2570.
   PubMedGoogle Scholar
• Nishikawa T, Matsumoto K, Tamura K, et al. Phase 1 dose-escalation study of single-agent veliparib in Japanese patients with advanced solid tumors. Cancer Sci. 2017 Sep;108(9):1834–1842.
   PubMed Web of Science ®Google Scholar
• Coleman RL, Sill MW, Bell-mcguinn K, et al. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015 Jun;137(3):386–391.
   PubMed Web of Science ®Google Scholar
• Steffensen KD, Adimi P, Jakobsen A. Veliparib Monotherapy to Patients With BRCA Germ Line Mutation and Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer: a Phase I/II Study. Int J Gynecol Cancer. 2017 Nov;27(9):1842–1849.
   PubMed Web of Science ®Google Scholar
• Boussios S, Karihtala P, Moschetta M, et al. Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: a Literature Review. Diagnostics (Basel). 2019 Aug 1;9(3):87. PMID: 31374917; PMCID: PMC6787707.
   Google Scholar
• Nishio S, Takekuma M, Takeuchi S, et al. Phase 1 study of veliparib with carboplatin and weekly paclitaxel in Japanese patients with newly diagnosed ovarian cancer. Cancer Sci. 2017 Nov;108(11):2213–2220.
   PubMed Web of Science ®Google Scholar
• Coleman RL, Fleming GF, Brady MF, et al. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N Engl J Med. 2019 Dec;381(25):2403–2415.
   PubMed Web of Science ®Google Scholar
• Kummar S, Ji J, Morgan R, et al. A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas. Clin Cancer Res. 2012 Mar 15;18(6):1726–1734.
   PubMed Web of Science ®Google Scholar
• Kummar S, Oza AM, Fleming GF, et al. Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer. Clin Cancer Res. 2015 Apr 1;21(7):1574–1582.
   PubMed Web of Science ®Google Scholar
• Hjortkjær M, Kanstrup H, Jakobsen A, et al. Veliparib and topotecan for patients with platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer with BRCA negative or unknown BRCA status. Cancer Treat Res Commun. 2018;14:7–12.
   PubMedGoogle Scholar
• LoRusso PM, Li J, Burger A, et al. Phase I safety, pharmacokinetic, and Pharmacodynamic study of the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) in combination with Irinotecan in patients with advanced solid tumors. Clin Cancer Res. 2016;22(13):3227–3237.
   PubMed Web of Science ®Google Scholar
• Gray HJ, Bell-mcguinn K, Fleming GF, et al. Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies. Gynecol Oncol. 2018 Mar;148(3):507–514.
   PubMed Web of Science ®Google Scholar
• Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. N Engl J Med. 2019 Dec 19;381(25):2416–2428.
   PubMed Web of Science ®Google Scholar
• Hettle R, McCrea C, Khoon Lee C, et al. Population-adjusted indirect treatment comparison (PAITC) of maintenance PARP inhibitor (PARPi) with or without bevacizumab versus bevacizumab in women with newly diagnosed ovarian cancer (OC). J Clin Oncol. 2020 May 20;38(15):6052.
   Web of Science ®Google Scholar
• Mirza MR, Åvall Lundqvist E, Birrer MJ, et al. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial. Lancet Oncol. 2019 Oct;20(10):1409–1419.
   PubMed Web of Science ®Google Scholar
• Dhawan MS, Bartelink IH, Aggarwal RR, et al. Differential toxicity in patients with and without DNA repair mutations: phase I study of carboplatin and talazoparib in advanced solid tumors. Clin Cancer Res. 2017;23(21):6400–6410.
   PubMed Web of Science ®Google Scholar
• Kummar S, Kinders R, Gutierrez ME, et al. Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol. 2009;27(16):2705–2711.
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Blais N, Mazieres J, et al. Randomized, placebo-controlled, phase II study of veliparib in combination with carboplatin and paclitaxel for advanced/metastatic non-small cell lung cancer. Clin Cancer Res. 2017 Apr 15;23(8):1937–1944.
   PubMed Web of Science ®Google Scholar
• Han HS, Dieras V, Robson ME, et al. Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: a randomized, phase 2 study. Abstract S2-05. Cancer Res. 2017 February 15;77(4). Supplement) S2-05. 10.1158/1538-7445.SABCS16-S2-05.
   Google Scholar
• Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013 Aug 22;500(7463):415–421.
   PubMed Web of Science ®Google Scholar
• Watkins JA, Irshad S, Grigoriadis A, et al. Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers. Breast Cancer Res. 2014 Jun 3;16(3):211 .
   PubMed Web of Science ®Google Scholar
• www.fda.gov/medical-devices/recently-approved-devices/foundationfocus-cdxbrca-loh-p160018s001.
   Google Scholar
• www.fda.gov/medical-devices/recently-approved-devices/myriad-mychoice-cdx-p190014.
   Google Scholar
• Alsop K, Fereday S, Meldrum C, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012 Jul 20;30(21):2654–2663.
   PubMed Web of Science ®Google Scholar
• Norquist B, Wurz KA, Pennil CC, et al. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol. 2011 Aug 1;29(22):3008–3015 .
   PubMed Web of Science ®Google Scholar
• Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014 Feb 1;20(3):764–775.
   PubMed Web of Science ®Google Scholar
• Zhang S, Royer R, Li S, et al. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol. 2011 May 1;121(2):353–357.
   PubMed Web of Science ®Google Scholar
• Tew WP, Lacchetti C, Ellis A, et al. PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline. J Clin OnCO. 2020 August 13;38(30):3468–3493.
   PubMed Web of Science ®Google Scholar
• Konstantinopoulos PA, Norquist B, Lacchetti C, et al. Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline. J Clin Oncol. 2020 Apr 10;38(11):1222–1245.
   PubMed Web of Science ®Google Scholar
• Da Cunha Colombo Bonadio RR, Fogace RN, Miranda VC, et al. Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management. Clinics (Sao Paulo). 2018 Aug 20;73(\(suppl 1)):e450s.
   PubMedGoogle Scholar
• Edwards SL, Brough R, Lord CJ, et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature. 2008 Feb 28;451(7182):1111–1115.
   PubMed Web of Science ®Google Scholar
• D’Andrea AD. Mechanisms of PARP inhibitor sensitivity and resistance. DNA Repair (Amst). 2018Nov;71:172–176.
   PubMed Web of Science ®Google Scholar
• Pettitt SJ, Krastev DB, Brandsma I, et al. Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance. Nat Commun. 2018 May 10;9(1):1849.
   PubMedGoogle Scholar